Literature DB >> 12410489

Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium.

Manjunath P Pai1, Keith A Rodvold, Paul C Schreckenberger, Ronald D Gonzales, Jennifer M Petrolatti, John P Quinn.   

Abstract

This retrospective cohort study revealed that linezolid resistance in vancomycin-resistant Enterococcus faecium was dependent on prior linezolid exposure and duration of linezolid therapy. These strains of E. faecium were resistant to the entire class of oxazolidinones.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12410489     DOI： 10.1086/344177

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  18 in total

1.  Development of Tyrocidine A analogues with improved antibacterial activity.

Authors:  Michael A Marques; Diane M Citron; Clay C Wang
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

2.  Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption.

Authors:  Marc H Scheetz; Stephanie A Knechtel; Michael Malczynski; Michael J Postelnick; Chao Qi
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

3.  In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program.

Authors:  Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Risk factors associated with linezolid-nonsusceptible enterococcal infections.

Authors:  Jessina C McGregor; Daniel M Hartung; George P Allen; Randy A Taplitz; Robin Traver; Tony Tong; David T Bearden
Journal:  Am J Infect Control       Date:  2012-02-22       Impact factor: 2.918

5.  Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Authors:  Lauren M Boak; Jian Li; Craig R Rayner; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

6.  Molecular analysis of linezolid resistance in clinical Enterococcus faecium isolates by polymerase chain reaction and pyrosequencing.

Authors:  P Schnitzler; K Schulz; C Lampson; M Geiss; H K Geiss
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-03       Impact factor: 3.267

Review 7.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Response to emerging infection leading to outbreak of linezolid-resistant enterococci.

Authors:  Marion A Kainer; Rose A Devasia; Timothy F Jones; Bryan P Simmons; Kelley Melton; Susan Chow; Joyce Broyles; Kelly L Moore; Allen S Craig; William Schaffner
Journal:  Emerg Infect Dis       Date:  2007-07       Impact factor: 6.883

9.  Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis.

Authors:  Michael Lobritz; Rebecca Hutton-Thomas; Steve Marshall; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium.

Authors:  B Schulte; A Heininger; I B Autenrieth; C Wolz
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.